Oncology (all articles)
Feasibility of discharge within 72 hours of major colorectal surgery: lessons learned after 5 years of institutional experience with the ERAS protocol.
10 Mar, 2022 | 10:21h | UTCRelated:
ERAS Guidelines for Perioperative Care in Elective Colorectal Surgery
Review: Enhanced Recovery After Surgery in Emergency Colorectal Surgery
Commentary on Twitter
A five year #retrospective #cohort study explored link between early post-op discharge and #ERAS (n=965)
-> adherence to >80% ERAS components associated with early discharge. Long operations, drains, and complications assoc w/longer stays.https://t.co/2nXBrKbg5D#SoMe4Surgery pic.twitter.com/h5P4YFC8zh
— BJS Open (@BjsOpen) March 2, 2022
Mapping systematic reviews of breast cancer survivorship interventions.
10 Mar, 2022 | 10:16h | UTC
Commentary on Twitter
🌐 Despite vast volume, review-level #BreastCancer #survivorship research is unevenly distributed and siloed. Strategic planning of future research, in consultation with survivors, is needed. ➡️ https://t.co/pxMp5XK8B8 #JCO #BCSM @EmmaBKemp1 #survonc pic.twitter.com/TRjOEJQbrw
— Journal of Clinical Oncology (@JCO_ASCO) March 5, 2022
Perspective: The time toxicity of cancer treatment.
10 Mar, 2022 | 10:15h | UTCThe Time Toxicity of Cancer Treatment – Journal of Clinical Oncology
RCT: Pain and health-related quality of life with olaparib vs. physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.
10 Mar, 2022 | 10:18h | UTCPain and health-related quality of life with olaparib versus physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia: a single-center experience.
10 Mar, 2022 | 10:09h | UTCRelated: Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology
Commentary on Twitter
OFID: In high-risk hematological patients w/ febrile neutropenia, antibiotic de-escalation and discontinuation prior to neutrophil recovery did not lead to an increase in infectious complications. https://t.co/eUer1fmoc6 #IDSAJournals @PaulSaxMD @DrJLi @FungalDoc @jobadd pic.twitter.com/HuGRYA8YW3
— IDSA (@IDSAInfo) January 5, 2022
Review: Interaction between modern radiotherapy and immunotherapy for metastatic prostate cancer.
10 Mar, 2022 | 10:02h | UTC
RCT: S-1 plus Oxaliplatin is non-inferior to Fluorouracil, Leucovorin plus Oxaliplatin as perioperative chemotherapy for locally advanced, resectable gastric cancer.
9 Mar, 2022 | 08:43h | UTC
Commentary on Twitter
In this RCT, S-1 plus oxaliplatin was noninferior to fluorouracil, leucovorin plus oxaliplatin as perioperative chemotherapy regimen for patients with locally advanced gastric cancer. https://t.co/W6fc1YcSBd
— JAMA Network Open (@JAMANetworkOpen) February 28, 2022
Review: Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
9 Mar, 2022 | 08:35h | UTC
RCT: Efficacy of HD201 vs. referent Trastuzumab in patients With ERBB2-positive breast cancer treated in the neoadjuvant setting.
9 Mar, 2022 | 08:22h | UTC
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1499791783735271426
RCT: Elective upper-neck vs. whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma.
9 Mar, 2022 | 08:17h | UTCElective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Elective Upper-Neck vs Whole-Neck Irradiation in Nasopharyngeal Carcinoma – The ASCO Post
Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma— Phase III trial also shows that upper-neck irradiation leads to fewer late toxicities – MedPage Today (link to abstract – $ for full-text)
Same-day discharge after brain tumor resection: a prospective pilot study.
9 Mar, 2022 | 08:19h | UTC
Commentary on Twitter
In select patients, same day discharge after #brainsurgery can be safe and effective, leading to improved patient feeling of wellness and satisfaction. #brain #cancer #costs @NSTumorSection https://t.co/TSGXcx9dmn pic.twitter.com/VVxuSiGTUX
— Journal of Neuro-Oncology (@JNeurooncol) March 2, 2022
AHA Scientific Statement: Cardio-oncology drug interactions.
8 Mar, 2022 | 09:53h | UTC
RCT: Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions.
8 Mar, 2022 | 08:28h | UTCRole of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Thoracic ultrasonography-guided pleurodesis in patients with malignant pleural effusions results in shorter hospital stay without reducing the success rate of the procedure at 3 monthshttps://t.co/hof4Rd2nUt
— K Pavithran (@drkpavithran) March 2, 2022
M-A: Site-specific therapy in cancers of unknown primary site.
8 Mar, 2022 | 08:23h | UTC
Systematic Review: Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.
8 Mar, 2022 | 08:24h | UTC
New research finds breast cancer overdiagnosis not as common as previously thought.
7 Mar, 2022 | 00:36h | UTCEstimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort – Annals of Internal Medicine (link to abstract – $ for full-text)
Breast cancer overdiagnosis may not happen as frequently as previously thought – ACP Internist
M-A: Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma.
7 Mar, 2022 | 00:07h | UTC
Commentary from the author on Twitter (thread – click for more)
In this global study of NAFLD-related HCC, we determine:
1.Prevalence
2.Clinical characteristics
3.% cirrhosis
4.Surveillance
5.Treatment allocation
6.Outcomes#LiverCancerSIG #LivertwitterFree to read @TheLancetOncol https://t.co/vwAeicpWxq
1/n pic.twitter.com/gM1BHVSwXl
— Daniel Huang (@DrHuangDQ) March 4, 2022
Multiparametric ultrasound vs. multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.
7 Mar, 2022 | 00:04h | UTCMultiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study – The Lancet Oncology (link to abstract – $ for full-text)
News Release: Ultrasound scan can diagnose prostate cancer – Imperial College London
Commentary on Twitter
In a prospective confirmatory study comparing multiparametric US vs MRI for prostate cancer detection in 306 men with an abnormal PSA or DRE findings, US detected 4.3% fewer clinically significant cancers despite 11.1% more pts being referred for a biopsy: https://t.co/ZFkiUTFJ5Y
— NatureRevClinOncol (@NatRevClinOncol) March 3, 2022
Lab study tested an extensive range of possibly effective drug combinations in breast, colon, and pancreatic cancer cells.
7 Mar, 2022 | 00:03h | UTCEffective drug combinations in breast, colon and pancreatic cancer cells – Nature
Commentaries:
New drug combinations found for resistant cancers – Wellcome Trust Sanger Institute
Study predicts treatment combinations for resistant cancers – Frontline Genomics
Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials.
6 Mar, 2022 | 23:32h | UTCCommentaries:
Women at higher risk of severe adverse events from cancer therapy – eCancer
Women Face Higher Risk for Severe AEs From Cancer Therapy – HealthDay
Commentary on Twitter
👀 Women had worse toxicity from #chemotherapy, #immunotherapy or #TargetedTherapy as compared to men in analysis of multiple @SWOG #clinicaltrials 👉 https://t.co/PjmnyJROb4 #leusm #CRCSM #LCSM @DrJoeUnger @DrDawnHershman pic.twitter.com/BJPZQoaI6g
— Journal of Clinical Oncology (@JCO_ASCO) February 23, 2022
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
A guideline for the outpatient management of glycemic control in people with cancer.
4 Mar, 2022 | 08:56h | UTC
Risk of cancer with angiotensin-receptor blockers increases with cumulative exposure: Meta-regression analysis of randomized trials.
4 Mar, 2022 | 08:49h | UTCCommentary: ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again – Medscape (free registration required)
Association between incident cancer and Guillain-barré syndrome development: a nationwide case-control study.
4 Mar, 2022 | 08:33h | UTCAssociation Between Incident Cancer and Guillain-Barré Syndrome Development: A Nationwide Case-Control Study – Neurology (link to abstract – $ for full-text)
News Release: Certain Types of Cancer May Increase the Risk of Developing Guillain-Barré – American Academy of Neurology
Phase 2, open-label RCT: Stereotactic body radiotherapy plus pembrolizumab and trametinib vs. stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection.
4 Mar, 2022 | 08:34h | UTCStereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)